Copenhagen, Denmark
Onsite/Online

ESTRO 2022

Session Item

Sunday
May 08
10:30 - 11:30
Room D2
Optimisation & algorithms in proton & ion radiotherapy
Jan Unkelbach, Switzerland;
Victor Hernandez, Spain
2250
Proffered Papers
Physics
11:00 - 11:10
The role of RBE and LET in treatment efficacy of carbon ion radiotherapy for sacral chordoma
Silvia Molinelli, Italy
OC-0452

Abstract

The role of RBE and LET in treatment efficacy of carbon ion radiotherapy for sacral chordoma
Authors:

silvia molinelli1, Giuseppe Magro2, Andrea Mairani3, Albina Allajbej4, Agnieszka Chalaszczyk5, Alfredo Mirandola2, Mario Ciocca2, Maria Rosaria Fiore5, Ester Orlandi5

1Fondazione CNAO, Medical physics, pavia, Italy; 2Fondazione CNAO, Medical Physics, pavia, Italy; 3Heidelberg Ion Beam Therapy Center , Radiation Oncology, Heidelberg, Germany; 4Istituto Nazionale dei Tumori, Radiation Oncology, Milano, Italy; 5Fondazione CNAO, Clinical Department, pavia, Italy

Show Affiliations
Purpose or Objective

To understand the role of relative biological effectiveness (RBE) modeling and dose-averaged linear energy transfer (LETd) distribution in the treatment of sacral chordoma (SC) patients with carbon ion radiotherapy (CIRT).

Material and Methods

We analyzed 50 SC patients consecutively treated before August 2018, with a local effect model (LEM)-based optimization, following a purely sequential boost schedule of 16 fractions (4.4 – 4.6 Gy(RBE) per fraction), with target shrinkage after 9 fractions. With a minimum follow-up of 12 months, 26 were classified as progressive disease; while 24 were reported as stable disease or partial regression and populated the control group for the analysis. To investigate patterns of failure, the relapse volume was contoured on the corresponding follow-up diagnostic sequence and described as in-field, field edge or out-of-field. Treatment plans were recalculated with the modified microdosimetric kinetic RBE model (mMKM) and target prescription dose (DRBE|50%), near-to-minimum- (DRBE|95%) and near-to-maximum- (DRBE|2%) doses were compared, between the two cohorts, in both RBE systems. LETd distribution was evaluated for in-field relapsed cases with respect to the control group. A subset of cases was mMKM-optimized to test feasibility of a new treatment protocol, aiming at the improvement of the therapeutic ratio. Finally, the variation of LETd evaluators in relation to the RBE model used for plan optimization was quantified. 

Results

Half of the relapse volumes were located in a well-covered high DLEM region, where DMKM and LETd resulted sub-optimal (Figure 1). Recalculated target DMKM|50% and DMKM|95% were respectively 10% and 18% lower than what we aimed at. Dosimetric evaluators showed no significant difference, in neither of the RBE models, between relapsed and control sets. On average, over these cases, median target LETd was significantly lower than the control cohort mean value (27 vs 30 keV/mm) (Figure 1b). Most notably, the volume receiving dose from high-LET particles (>50 keV/mm) lay substantially below recently reported data on the Japanese experience. mMKM-optimization generated plans with LETd distributions comparable to LEM-based, with no statistically significant difference in neither of the considered criteria.


Figure 1 Optimized DLEM (a), recalculated DMKM (b) and corresponding LETd (c) distributions of a high-dose relapsed case. The colorwash scale normalization values are: a) DLEM = 70.4 Gy (RBE), b) DMKM = 67.2 Gy (RBE) and c) LETd = 50 keV/mm. Plotted contours indicate the low dose - CTV (9 fractions - yellow), high dose - CTV (16 fractions - orange), GTV (red) and relapse (light blue) volumes.

Conclusion

Multi model RBE-evaluation and LET-based optimization could play a key role in the enhancement of the therapeutic ratio of CIRT for large radioresistant tumors such as sacral chordomas.